Issue 3

Will A New Generation Of Non-Opioid Therapies Cure The Opioid Epidemic?

Why not sign up for our future email newsletters? Sign up here.

Included in this issue:

LEAD STORY

Non-Opioid Drugs Show Promise in a New Generation of Pain Management Therapies

Kicking off with non-opioid drugs news, Latigo Biotherapeutics have just announced $135 million in Series A financing to develop non-opioid medicines for patients suffering from acute and chronic pain​​. Since launching in 2020, the company has been working on a portfolio of novel pain therapeutics, focusing on drugs that use a selective Nav1.8 inhibitor to block pain receptors.

Read more here.

FEATURED STORIES

AbbVie Acquires ImmunoGen For Oncology Pipeline

Read more here.

Firefly Bio Launches with $94 Million for Innovative Cancer Therapy Platform

Read more here

Lantern Pharma Progresses Novel ADC Initiative in Various Solid Cancer Types

Read more here.

Nanoform Wins Business Finland grant of EUR 4.3M for its R&D in Nanoparticle-Enabled Formulation

Read more here.

BMS Pay $674m for Generative AI Drug Discovery

Read more here.

Biotech Startups Merge Into Alys Pharmaceuticals With Pipeline of Dermatology Medicines

Read more here.

Aizon Secures $20M for AI-Based Pharma Manufacturing & Next-Gen Electronic Batch Record Systems

Read more here.

10 Year High For Biotech Bankruptcies

Read more here.

Revival in US Biotech Financing Marks End of Two-Year Slump

Read more here.

BioAge Raises $170 Million to Develop New Obesity Therapies

Read more here.

European Commission Approves First CRISPR Gene-Edited Therapy for Blood Disorder

Read more here.

Pfizer & Astellas Feature In Super Bowl Commercials 

Read more here.

FDA Cracks Down on Illegal Weight Loss Drugs

Read more here.

FDA Schedules June Deadline for Potential Approval and Broader Usage of Sarepta's Duchenne Genetic Treatment

Read more here.